The initiative targets patients with complex medical needs, where every minute of advanced intervention withheld is a minute of avoidable deterioration. That’s a meaningful shift in how Abu Dhabi is thinking about pre-hospital care, and it fits squarely within the emirate’s broader push to build a health system that performs at the point of need, not just within facility walls.

How does it work?

The new ambulances are equipped to handle high-acuity cases from the first moments of emergency response. While full technical specifications are still being detailed publicly, the fleet is designed to support conditions requiring advanced monitoring, intervention, and clinical decision-making on the move. Key reported capabilities include:

• Advanced life support equipment tailored for complex and critical conditions
• Integrated smart systems to support real-time clinical monitoring during transport
• Specialist-level configuration that goes beyond standard emergency medical service vehicles
• Coordination capability between the ambulance crew and receiving hospital teams

The joint deployment between DoH and ADCDA also signals stronger institutional coordination between the health regulatory body and the civil defence infrastructure, which manages emergency response across the emirate.

Why does it matter?

In emergency medicine, the concept of the “golden hour” is well established. What is less often discussed is how much of that window is consumed by transport with limited clinical capability. For stroke, cardiac arrest, major trauma, or severe respiratory failure, the difference between an ambulance that monitors and one that actively treats can determine both survival and long-term outcome.

Abu Dhabi has invested heavily in hospital infrastructure over the past decade. But pre-hospital care has historically been harder to upgrade at scale. This fleet suggests the emirate is now treating the space between emergency call and hospital admission as a clinical environment in its own right, not just a logistical corridor.

For clinicians, that matters. For policymakers designing health outcomes frameworks, it matters too. And for insurers and health economists watching the cost of delayed intervention, it is a model worth tracking.

The context

This launch sits within a wider pattern across the GCC, where health authorities are investing in emergency systems as part of national modernisation agendas. In Saudi Arabia, Vision 2030 has included emergency care network development as part of its health transformation programme. The UAE’s own health targets, set under various national and emirate-level strategies, include measurable improvements in emergency response times and outcomes.

Abu Dhabi, as the UAE’s capital and largest emirate by area, has particular geographic incentive to get pre-hospital care right. So this fleet is both a clinical statement and a strategic one. And if the outcomes data follows, it could set a benchmark that other GCC health authorities will be watching closely.

The post Abu Dhabi deploys smart ambulances built for its most complex medical cases appeared first on DH Arab.

The approval was issued under the SFDA’s Innovative Medical Devices Pathway, a dedicated fast-track route created to bring advanced health technologies to the Saudi market without compromising on safety or clinical evidence. The device, a first of its kind in the Kingdom, uses next-generation biosensor technology to deliver simultaneous, continuous readings of both glucose and ketone levels. No switching between tests, no separate strips, no delay.

How does it work?

The device is a wearable continuous monitor built on biosensor technology that tracks two biomarkers at once. Traditional continuous glucose monitors, or CGMs, measure glucose only. This device adds real-time ketone tracking to that feed, giving clinicians and patients a more complete picture of metabolic status at any given moment. The SFDA’s review covered full technical and clinical documentation, safety and performance data, and verified clinical trial results before authorization was granted.

• Continuous, real-time monitoring of blood glucose levels
• Simultaneous tracking of ketone levels around the clock
• Early detection of physiological changes linked to diabetic ketoacidosis
• Support for faster clinical decision-making in high-risk patients
• Designed for use by both patients and healthcare providers

Why does it matter?

Diabetic ketoacidosis, or DKA, is dangerous because it often progresses fast. By the time ketone levels are high enough to cause symptoms, the patient may already be in serious trouble. A device that catches the early signs of both elevated glucose and rising ketones in real time gives clinicians a meaningful head start. That is not a small thing in emergency and intensive care settings, where minutes matter.

But this also changes something for patients managing diabetes day to day. Knowing your ketone levels in real time, not just your glucose, means you can act earlier, adjust faster, and potentially avoid a hospital visit altogether. That shift toward proactive management, rather than reactive treatment, is central to how modern healthcare systems want to operate. Saudi Arabia now has a regulatory-approved tool that supports exactly that.

The context

This approval fits squarely into the Health Sector Transformation Program, one of the core pillars of Saudi Vision 2030, which has made accelerating the adoption of advanced medical technologies a national priority. The SFDA’s Innovative Medical Devices Pathway is one of the practical mechanisms built to make that happen, and this authorization shows it working as intended.

The Kingdom also has a genuine clinical need here. Diabetes prevalence across the GCC remains among the highest in the world, and Saudi Arabia is no exception. Better monitoring tools are not a luxury in this context. And being among the first regulators globally to authorize this class of device positions the SFDA alongside agencies like the FDA and CE mark bodies in Europe, which is a meaningful signal about the maturity of Saudi Arabia’s regulatory infrastructure. That reputation matters when attracting medical technology companies to seek early approval in the Kingdom rather than treating it as a secondary market.

The post Saudi Arabia becomes one of the first countries to approve a device that monitors glucose and ketones simultaneously appeared first on DH Arab.

The trial enrolled more than 1,100 patients with higher-risk or advanced melanoma whose detectable cancer had been fully removed through surgery. Patients received either Merck’s immunotherapy Keytruda alone, or Keytruda combined with the experimental mRNA vaccine. The combination met the trial’s primary goal: patients who received it went significantly longer without their melanoma returning. The treatment also reduced the risk of the cancer spreading to other parts of the body.

Merck shares climbed more than 10% on the news. But the scale of Moderna’s jump, from roughly $25 billion in market capitalization before the announcement, reflects just how much was riding on these results for the smaller company. As Leerink Partners analyst Mani Foroohar noted ahead of the data release, this Phase 3 readout was effectively a make-or-break moment for Moderna’s valuation.

How does it work?

The vaccine is not a standard shot. Every tumor carries a unique set of genetic mutations, even among patients with the same cancer type. Rather than applying a fixed formula across all patients, the vaccine is designed around each individual’s specific tumor mutations. The goal is to train the patient’s immune system to recognize those unique markers and attack them. That targeted immune response is then combined with Keytruda, which works by releasing the brakes on the immune system and allowing it to fight cancer more effectively.

Merck’s head of oncology early development, Dr. Jane Healy, described the results as a “clinically meaningful improvement” over Keytruda alone, and said the side effects were comparable to those seen with conventional vaccines. That tolerability finding matters. Patients with melanoma already face surgery and prolonged anxiety about recurrence. A treatment that adds meaningful protection without a severe side-effect burden changes the risk-benefit calculation significantly.

Why does it matter?

Melanoma accounts for only around 1% of all skin cancers, but it is responsible for the large majority of skin cancer deaths. Most recurrences happen within the first two to three years after initial treatment. So the window for post-surgical intervention is narrow, and the consequences of missing it are serious.

But the bigger story here is not melanoma alone. The results validate a personalized treatment model that Merck and Moderna have spent decades building. The companies are already studying the vaccine in trials for non-small cell lung cancer, bladder cancer, and renal cell carcinoma. A positive Phase 3 result in melanoma is the first real proof that this class of therapy can work at scale, and it opens the door to broader applications across cancer types.

The context

For the Gulf region, these results arrive at a moment of serious investment in oncology infrastructure. Saudi Arabia’s Vision 2030 health strategy includes a significant push to expand cancer care capacity and reduce dependence on medical travel abroad. The UAE has made similar commitments through its national health agenda, with Abu Dhabi and Dubai both investing in genomics and precision medicine programs.

Personalized cancer vaccines sit squarely within the precision medicine model that GCC health authorities have been working toward. The clinical and regulatory pathway will unfold primarily in the US and Europe over the coming months, with Merck and Moderna expected to begin discussions with regulators soon. But the commercial and policy implications for this region are real. Health systems that have already invested in genomic sequencing infrastructure will be better positioned to adopt this class of therapy when it reaches approval.

Moderna CEO Stephane Bancel called the results “a big moment for medicine, a big moment for patients.” That may be understating it. If this personalized approach holds up across additional cancer types, the implications for how oncology is practiced globally, including across the GCC, could be substantial.

The post Merck and Moderna’s personalized cancer vaccine clears its first major late-stage trial appeared first on DH Arab.

The two companies announced a strategic agreement that gives inDrive drivers access to Vezeeta’s “Shamel” programme, an annual healthcare subscription that offers discounts of up to 80% on medical services. The deal is not a generic corporate wellness gesture. It is structured around inDrive’s existing driver loyalty tiers, which means the benefits are calibrated to reward engagement with the platform.

How will it work?

Drivers at the top of inDrive’s loyalty structure, classified as “Legendary” drivers, will receive complimentary Shamel subscriptions. All other inDrive drivers, and their families, are eligible for a 25% discount on Shamel subscriptions. The Shamel programme itself has no age restrictions, no exclusions for chronic conditions, and no caps on how many times a subscriber can access services throughout the year. There is also no requirement for prior authorisation, which removes one of the most common friction points in healthcare access.

Through the Vezeeta app, subscribers can:

• Book doctor consultations
• Order pharmacy products
• Schedule phone-based follow-up appointments
• Request home visits from doctors
• Book laboratory tests and radiology services

Alaa El-Din Shalaby, General Manager of inDrive Egypt, described the move as a natural extension of the company’s commitment to its driver community. “Our drivers are the driving force behind everything we do,” he said, “and supporting their health and well-being is among our top priorities.”

Why does it matter?

Gig and platform workers across the Arab world are a growing labour segment, but they rarely enjoy the occupational health benefits that come with formal employment. No employer-sponsored insurance. No sick leave. And in many cases, deferred medical care because the cost and time commitment feels unmanageable.

This partnership does not solve that structural problem. But it does make a practical difference. A driver who can book a specialist consultation at 80% off, without navigating insurance paperwork, is more likely to actually seek care. And that matters at scale. inDrive operates in more than 1,200 cities across 48 countries, and its app has been downloaded over 400 million times, making it the second most downloaded smart mobility application globally.

Dr. Ola Ali El-Din, Chief Operating Officer at Vezeeta, said the deal fits the company’s broader strategy of building partnerships with organisations that share a genuine interest in expanding healthcare access. “inDrive was one of the key companies where we saw a strong commitment to providing better healthcare solutions for its drivers,” she said.

The context

Vezeeta is one of the region’s most established health-tech platforms, operating across the Middle East and Africa with a network of more than 30,000 healthcare providers. The Shamel subscription model reflects a wider shift in how digital health platforms are approaching affordability. Rather than relying solely on insurance integration, subscription-based access is emerging as a parallel route to making routine care financially manageable.

In Egypt specifically, where out-of-pocket healthcare spending remains significant, that approach carries real weight. The government’s own health coverage reforms under Egypt Vision 2030 have made progress, but private-sector initiatives that extend affordable care to informal and semi-formal workers are filling gaps that public programmes have not yet reached. Partnerships like this one, anchored in existing digital platforms with large user bases, may prove to be one of the more efficient ways to move the needle on population health access in the near term.

The post inDrive and Vezeeta join forces to bring subsidised healthcare to Egypt’s ride-hailing drivers appeared first on DH Arab.

The direction is clear. Across the Emirates, health authorities are integrating artificial intelligence, data analytics, genomics and precision medicine into a care model that prioritises identifying problems before they become serious. This runs alongside expanded preventive screening programmes and public health awareness campaigns. Together, these elements are reshaping what the healthcare system is actually for.

This is not a minor operational adjustment. It reflects a broader national ambition. The UAE’s leadership has consistently framed health as a pillar of long-term economic resilience, not simply a social service. A population that is healthier, earlier, costs less and contributes more. The logic is straightforward, even if the execution is complex.

How does it work?

The shift toward proactive care draws on several converging tools. AI is being used to analyse patient data and flag individuals at elevated risk before symptoms appear. Genomics allows clinicians to understand a patient’s genetic predispositions and tailor interventions accordingly. Precision medicine takes that a step further, matching treatments to individual biological profiles rather than applying population-wide protocols.

Preventive screenings, particularly for conditions like diabetes, cardiovascular disease and certain cancers, are also being scaled up. And health awareness programmes are being redesigned to move beyond generic messaging toward targeted communication that reflects specific risk profiles and demographics. So the system is not just collecting more data. It is trying to act on it earlier and more precisely.

Why does it matter?

The UAE, like much of the GCC, faces a significant burden from non-communicable diseases. Diabetes prevalence is among the highest in the world. Cardiovascular conditions are a leading cause of mortality. These are largely preventable or manageable when caught early. A healthcare model built around treatment alone will always be fighting from behind.

But there is also a structural argument. Healthcare costs rise when conditions are diagnosed late. Shifting the point of intervention earlier, from the emergency room to the clinic, from the clinic to the screening, reduces pressure on acute care capacity and brings costs down over time. For a country that has committed significant public investment to healthcare infrastructure, getting more from that investment through prevention makes fiscal sense.

The context

This direction fits within the UAE’s broader Vision 2030 framework and aligns with national strategies around digital health and data-driven public services. The country has already made substantial moves in health data infrastructure, including electronic medical records and national health platforms. AI and genomics are the next logical layer.

• AI-powered risk stratification for early disease detection
• Genomic profiling to inform personalised treatment plans
• Expanded national screening programmes for high-prevalence conditions
• Data analytics integrated into clinical decision-making
• Targeted public health campaigns based on population risk data

Across the GCC, Saudi Arabia’s Vision 2030 health targets and Qatar’s National Health Strategy reflect similar thinking. The region is moving, collectively, toward a model where the health system’s success is measured not just by how well it treats illness, but by how much of it is prevented in the first place.

The post The UAE is betting on prevention, not just treatment appeared first on DH Arab.

First Gulf Company (FGC) has announced it will introduce the Certified Healthcare Technology Manager (CHTM) certification pathway in Saudi Arabia, working alongside the Biomedical Engineering Technology Society (BMET). The two organisations will sign a Memorandum of Understanding on 23 August 2026 to formalise the arrangement.

The CHTM credential is awarded internationally by the Association for the Advancement of Medical Instrumentation (AAMI). It is a recognised benchmark for professionals responsible for managing the medical equipment and health technology systems that clinical staff depend on daily. For Saudi Arabia, this is the first time the pathway has been made available locally.

How will it work?

FGC will deliver the certification pathway through its Facility Management Division, with Saudi engineers among the first in the Kingdom to undertake the programme. BMET, the Kingdom’s professional body for biomedical engineering, is accredited by the Saudi Commission for Health Specialties (SCFHS) and brings the regulatory credibility needed to anchor the programme within the national health system.

The two organisations together create a pathway that is both internationally recognised and locally grounded. Engineers who complete the programme will hold a credential that carries weight beyond Saudi borders, while the content is directly relevant to the realities of managing health facilities across the Kingdom.

Why does it matter?

Medical equipment fails. When it does, patient safety is at risk and clinical workflows break down. The people responsible for maintaining and managing that equipment need more than technical skills. They need structured, validated expertise, and a professional standard that holds them to account.

The CHTM credential addresses exactly that. And bringing it to Saudi Arabia means the Kingdom’s health facilities can now develop in-house talent to a globally recognised standard, rather than relying solely on external expertise. That’s a meaningful shift, both for workforce development and for the long-term reliability of the country’s healthcare infrastructure.

• Validates the technical and managerial competency of healthcare technology professionals
• Recognised internationally through AAMI, one of the most credible bodies in medical instrumentation
• Delivered locally through BMET, which is accredited by SCFHS
• Directly supports the development of Saudi national talent in a specialised health sector role

The context

Saudi Vision 2030 has placed significant weight on building a resilient, locally managed healthcare system. Part of that means reducing dependence on expatriate expertise in technical fields and investing in the capabilities of Saudi professionals. FGC, founded in 2001 and a systems integration partner across healthcare, broadcasting, and critical infrastructure, positions this initiative as a direct expression of that national commitment.

But the significance extends beyond Vision 2030 rhetoric. Across the GCC, health systems are expanding rapidly. New hospitals are opening, digital health infrastructure is being built out, and the complexity of medical technology is increasing. The demand for professionals who can manage that complexity to a consistent standard is only going to grow. Saudi Arabia, by introducing the CHTM pathway now, is moving ahead of that curve.

The post Saudi Arabia gets its first internationally accredited healthcare technology management certification appeared first on DH Arab.

The initiative is delivered in collaboration with the Emirates Foundation and Active, and it targets a demographic that is often underserved by conventional healthcare outreach despite being among the most in need of early intervention and consistent health monitoring.

How does it work?

Healthy Horizons operates as a direct outreach effort, bringing health services and education to senior citizens rather than expecting them to seek it out themselves. The programme includes on-the-ground health screenings, wellness education sessions, and support for digital health tools, helping older Emiratis use connected health technologies that many in their age group have had limited exposure to.

It is designed to reach participants through the Family Development Foundation’s existing community networks, giving the programme a ready-made channel into households and community centres across Abu Dhabi. The involvement of Emirates Foundation and Active adds further capacity for on-the-ground delivery and physical wellness programming.

Key components of the programme include:

• Preventive health screenings tailored to common conditions in the elderly population
• Healthy ageing education covering nutrition, mobility, and chronic disease management
• Digital health literacy sessions to help seniors use telehealth platforms and health monitoring apps
• Physical activity and wellness activities delivered through Active
• Community engagement through Family Development Foundation networks

Why does it matter?

The UAE’s population is ageing. That is not a crisis, but it is a planning challenge that the health sector needs to get ahead of. Preventive care, when it works, reduces hospitalisation rates, lowers long-term costs, and improves quality of life. For senior citizens, the window for meaningful prevention is often narrow, which makes early and consistent engagement critical.

Digital health inclusion is a separate but equally important thread here. Telehealth and remote monitoring tools have grown significantly across the GCC, but adoption among older populations has lagged. If senior citizens cannot use these tools, they miss out on services increasingly being built around them. Healthy Horizons addresses that gap directly, and that is worth paying attention to.

So this is not just a corporate social responsibility exercise. It is a structured attempt to extend the reach of the UAE’s health infrastructure into a community segment that conventional clinic-based models often miss.

The context

PureHealth is the largest healthcare platform in the Middle East, with deep ties to Abu Dhabi’s health system. Its involvement in community-level outreach reflects a broader shift in how major health groups in the UAE are thinking about their role. Hospitals and specialist centres remain central, but population health, and the idea of keeping people well rather than simply treating them when they are sick, is gaining serious institutional weight.

This sits squarely within the priorities of the UAE’s national agenda. Abu Dhabi’s Department of Health has consistently pushed preventive care as a cornerstone of the emirate’s health strategy, and the focus on senior Emiratis connects to wider social policy goals around family cohesion and community support. The Family Development Foundation’s involvement is a deliberate signal that health and social welfare are being treated as interconnected rather than separate domains.

Across the GCC, Saudi Arabia’s Vision 2030 health transformation and Kuwait’s digital health investments reflect a similar direction of travel. The Healthy Horizons launch is a local expression of a regional shift, one that positions community-based, preventive, and digitally inclusive care as the next frontier for Gulf health systems.

The post PureHealth launches Healthy Horizons to bring preventive care to Abu Dhabi’s elderly appeared first on DH Arab.

Al Qassimi Women’s and Children Hospital, operating under Emirates Health Services (EHS), has introduced the Omnipod 5 Automated Insulin Delivery System for children living with Type 1 diabetes. It is the first deployment of this technology across any EHS facility, and it signals a meaningful step forward in how the UAE’s public health system approaches chronic disease management in younger patients.

The move fits squarely within the UAE’s broader push to modernise its healthcare infrastructure. EHS has been expanding its use of advanced medical technologies across multiple specialties, and this rollout reflects that direction. For families managing Type 1 diabetes in a child, the stakes are high and the daily burden is real. A system that reduces that burden while improving clinical outcomes is not a small thing.

How does it work?

The Omnipod 5 is a tubeless, wearable insulin delivery system that communicates with a continuous glucose monitor to adjust insulin doses automatically. Unlike traditional pump systems, it requires no tubing and attaches directly to the skin. The system uses a built-in algorithm to read glucose data and respond in real time, increasing or reducing insulin delivery based on the child’s current levels and trends.

Key features of the system include:

• Automated insulin adjustments without manual input from the patient or caregiver
• Tubeless design that is less intrusive for active children
• Integration with continuous glucose monitoring for real-time responsiveness
• Smartphone compatibility, allowing caregivers to monitor remotely

So the system does not simply deliver insulin on a fixed schedule. It learns, adjusts, and responds. For a child in school or at sport, that matters enormously.

Why does it matter?

Type 1 diabetes requires constant vigilance. Parents of children with the condition manage a relentless cycle of glucose checks, dose calculations, and intervention, often through the night. Automated insulin delivery systems reduce that cognitive load significantly. Studies have shown they also improve time-in-range metrics, the percentage of hours a patient spends within a healthy glucose window, which correlates directly with long-term health outcomes.

For EHS, this is also about equity. Introducing the Omnipod 5 within a public hospital means this technology is not limited to those who can afford private care. That distinction matters in a system serving a wide and diverse patient population.

The context

The UAE has one of the highest rates of diabetes in the world. While much of that burden falls on adults with Type 2 diabetes, Type 1 among children is a growing clinical priority. The country’s Vision 2030-aligned health strategies, and EHS’s own digital health agenda, have consistently pointed toward technology adoption as central to improving outcomes.

This launch is one data point in that larger effort. But for the families it directly affects, it is the most important one.

The post EHS rolls out tubeless insulin pump technology for children with Type 1 diabetes appeared first on DH Arab.

Mastek, listed on both the NSE and BSE in India, operates more than 4,700 specialists across 40 countries and carries a 96% client retention rate. That kind of institutional credibility with government health authorities and large health systems is not something a new market entrant builds quickly. So for Innovaccer, which has built its autonomous operations platform, Gravity, with strong traction in the US and the Middle East, Mastek solves a real market-access problem in the UK and Europe. For Mastek, the deal brings a purpose-built, Best in KLAS healthcare AI platform into its portfolio without the cost of building one from scratch.

How will it work?

Under the partnership, Mastek will deploy and localise Innovaccer’s full suite of healthcare AI applications across existing and new markets. The combined offering covers:

• Agentic revenue cycle management, including prior authorisation, coding, and denials
• Population health and value-based care programs
• Payer performance across Stars ratings, risk adjustment, and utilisation management
• Patient access and contact centre operations, combining Mastek’s digital front door and conversational AI expertise with Innovaccer’s omnichannel scheduling and referral agents

All of this runs on Innovaccer’s unified clinical and financial data layer, which handles interoperability and governance across each deployment.

Why does it matter?

Healthcare organisations across the GCC and beyond are under growing pressure to reduce administrative cost and improve operational throughput. AI agents that can automate prior authorisation, coding, and patient scheduling address exactly the workflows that consume the most capacity. But technology alone rarely closes the deal. Local delivery credibility, regulatory familiarity, and existing government relationships do. Mastek brings all three.

For the Middle East specifically, this partnership adds structured delivery capacity to a region where health system digitalisation is moving fast, driven by Saudi Vision 2030 and the UAE’s national health transformation agenda. Innovaccer already has a footprint here. Mastek’s network strengthens the ability to execute at the pace those markets now demand.

The context

Innovaccer was recently named a leader in the inaugural Gartner Magic Quadrant for Healthcare Provider Industry Cloud Platforms. That recognition, combined with Mastek’s independent decision to build its delivery practice around Gravity, sends a clear signal to the market about where enterprise healthcare AI investment is consolidating. The partnership is not a pilot. It’s a coordinated go-to-market push across four regions, targeting health systems and payers where the appetite for AI-driven operational change is high but the right platform and delivery partner have historically been missing.

The post Innovaccer and Mastek join forces to bring agentic AI to healthcare across four regions appeared first on DH Arab.

The US-based electronic health record giant has released Care Everywhere Diagnostic Image Exchange, a feature that allows clinicians using Epic to retrieve full diagnostic-quality images from other health systems with a single click. That means CTs, MRIs, X-rays, and similar scans can travel between institutions without manual requests, without discs, and without patients having to act as their own medical couriers.

The release, dated August 2026, is available across the Epic community immediately.

How does it work?

Diagnostic images are typically stored in separate image archiving systems, outside the electronic health record itself. Until now, those systems did not share a common technical standard, which made cross-institution image exchange slow, manual, and often impossible. Clinicians could access written radiology reports and lower-resolution reference images through Epic’s existing Care Everywhere network, but the full diagnostic files stayed locked in their originating system.

Epic has changed that by building on open image exchange standards and routing them through its existing interoperability pipelines. When a clinician identifies a relevant prior scan at another organisation, they can now retrieve the full diagnostic image directly from that organisation’s archive. One click. No phone calls, no courier, no disc.

The system also connects to Epic’s existing duplicate-order detection tools. Those checks already flag when a patient has had a scan performed elsewhere, preventing more than 21,000 repeat scans every year across the Epic network. Now, when a duplicate is flagged, the clinician can actually pull the original image rather than simply knowing it exists somewhere.

Why does it matter?

The clinical case is straightforward. Patients sometimes undergo repeat scans not because their condition requires it, but because their clinician cannot access what was already done at another facility. That delays diagnosis, adds unnecessary radiation exposure, and drives up costs. Faster image access means faster decisions, and faster decisions mean earlier treatment.

But the administrative dimension matters just as much. Manual image retrieval is a burden that sits across radiology departments, medical records teams, and front-line clinicians alike. Eliminating that friction has real workforce implications, particularly in health systems already stretched thin.

Epic’s director of interoperability, Matt Doyle, also used the announcement to push for broader adoption of open image-sharing standards through TEFCA, the federally sponsored interoperability framework in the United States. If TEFCA adopts these standards, any health system in the country could eventually participate in diagnostic image exchange, not just Epic users. That is a significant policy ambition sitting behind what looks, on the surface, like a product update.

The context

For health systems across the GCC, this development is worth watching closely. The region is investing heavily in health data interoperability as part of broader digital transformation agendas. Saudi Arabia’s Vision 2030 health pillar, the UAE’s unified health data initiatives, and similar programmes across the Gulf all share a common goal: connected care that follows the patient, not the institution.

The challenge Epic is solving in the US, fragmented image storage, manual retrieval, and patients acting as their own records carriers, is not unique to North America. Any health system operating across multiple facilities or referral networks faces the same problem. The technical approach Epic has taken, building on open standards rather than proprietary pipelines, is exactly the kind of architecture that regional health authorities should be examining as they design their own interoperability frameworks.

Epic’s move also signals something broader about where the health technology sector is heading. The push for open standards in image exchange, combined with real-time prior authorisation checks and AI-supported clinical visits announced alongside this release, points to an industry that is finally prioritising connectivity over competition. That shift, if it holds, will matter everywhere.

The post Epic launches one-click diagnostic image sharing across health systems appeared first on DH Arab.